Table 2.
Baseline anti-hyperglycemic medications
| Baseline anti-hyperglycemic medication | All patients (n = 204) | Type 2 cohort (n = 175) | Type 1/LADA cohort (n = 29) | Insulin cohort (n = 180) | Naïve cohort (n = 24) |
|---|---|---|---|---|---|
| Basal insulin dose (U/day) | |||||
| Patient reporteda | – | 53 ± 28 | 39 ± 17 | 51 ± 27 | – |
| Lower limit prescribed | – | 56 ± 31 | 41 ± 16 | 54 ± 30 | – |
| Upper limit prescribed | – | 60 ± 31 | 49 ± 22 | 58 ± 30 | – |
| Prescribed range | – | 12–120 | 18–100 | 12–220 | – |
| Insulin TDD (U/day) | |||||
| Patient reporteda | – | 78 ± 46 | 69 ± 31 | 77 ± 44 | – |
| Lower limit prescribed | – | 86 ± 50 | 86 ± 35 | 86 ± 48 | – |
| Upper limit prescribed | – | 98 ± 55 | 104 ± 41 | 99 ± 53 | – |
| Prescribed range | – | 16–310 | 31–180 | 16–310 | – |
| Concomitant medicationsb | |||||
| Metformin | 89 (44) | 80 (46) | 9 (31) | 77 (43) | 12 (50) |
| Sulfonylurea | 43 (21) | 40 (23) | 3 (10) | 34 (19) | 9 (38) |
| GLP-1 receptor agonist | 40 (20 | 37 (21) | 3 (10) | 38 (21) | 2 (8) |
| DPP-4 inhibitor | 18 (9) | 18 (10) | 0 (0) | 16 (9) | 2 (8) |
| DPP-4 I/Metformin | 17 (8) | 17 (10) | 0 (0) | 12 (7) | 5 (21) |
| SGLT-2 inhibitor | 11 (5) | 10 (6) | 1 (3) | 10 (6) | 1 (4) |
| TZD | 8 (4) | 8 (5) | 0 (0) | 8 (4) | 0 (0) |
Data are n (%) or mean ± SD
DDP-4 dipeptidyl peptidase-4, GLP-1 glucagon-like peptide-1, LADA latent autoimmune diabetes in adults, SGLT-2 sodium-glucose co-transporter-2, TDD total daily dose, TZD thiazolidinedione
aPatient reported mean insulin doses reflective for 121, 23, and 142 patients in type 2, type 1/LADA, and insulin cohorts, respectively
bConcomitant medications prescribed for <2% of population not included. Multiple medications are possible per patient